Advertisement

Discomfort symptoms reduction and ocular surface parameters recovery with Artelac Rebalance treatment in mild–moderate dry eye

Discomfort symptoms reduction and ocular surface parameters recovery with Artelac Rebalance treatment in mild–moderate dry eye

Eur J Ophthalmol 2013; 23(4): 488 - 495

Article Type: ORIGINAL ARTICLE

DOI:10.5301/ejo.5000267

Authors

Piera Versura, Vincenzo Profazio, Giuseppe Giannaccare, Michela Fresina, Emilio C. Campos

Abstract

Purpose: To evaluate Artelac Rebalance® eyedrops’ efficacy in symptoms reduction, ocular surface parameters recovery, and tolerability in the treatment of mild to moderate dry eye.
Methods: Fifteen patients were enrolled. Inclusion criteria were Ocular Surface Disease Index (OSDI) score >16, tear film break-up time (TFBUT) <10 seconds, Schirmer test I >10 mm/5 min, and mild ocular surface damage (Oxford grading) ≤3. Artelac Rebalance® eyedrops were administered 3 times daily for 2 months. Patients were evaluated at enrollment, after 2 days of washout (baseline), and after 1 and 2 months of treatment. Parameters for ocular discomfort (OSDI score), tear film quality (Schirmer 
test I, TFBUT, tear osmolarity), ocular surface damage (fluorescein staining, conjunctival imprint cytology), and inflammation (scraping cytology and exuded serum albumin) were measured. Tolerability and satisfaction were assessed by validated questionnaires.
Results: At endpoint versus baseline, all variables showed a statistically significant improvement (paired Student t test, p<0.01 for all parameters) as follows: OSDI score (21.9 ± 10.6 vs 35.8 ± 12.2), TFBUT (6.5 ± 1.1 s vs 5.2 ± 2.3 s), Oxford grading of corneal and conjunctival damage (0.56 ± 0.50 vs 1.16 ± 0.37), tear osmolarity (294.6 ± 2.1 mOsm/L vs 303.1 ± 4.6 mOsm/L), conjunctival goblet cell density/mm2 (140.8 ± 43.3 cells/mm2 vs 115.1 ± 15.8 cells/mm2), scraping cytology score (2.9 ± 1.0 vs 
4.2 ± 1.3), and percentage of serum albumin in tears (9.2% ± 4.8% vs 24.1% ± 10.8%). Tolerability and satisfaction were scored high, with no adverse events reported.
Conclusions: Application of Artelac Rebalance® eyedrops for 2 months in mild to moderate dry eye resulted in a reduction of ocular inflammation parameters, ocular surface damage, and subjective discomfort symptoms, with a parallel improvement in tear film quality (measured by TFBUT and osmolarity).

Article History

This article is available as full text PDF.

  • If you are a Subscriber, please log in now.

  • Article price: Eur 36.00
  • You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
  • If you are not a Subscriber you may:
  • Subscribe to this journal
  • Unlimited access to all our archives, 24 hour a day, every day of the week.

Authors

  • Versura, Piera [PubMed] [Google Scholar]
    Ophthalmology Unit, Alma Mater Studiorum University of Bologna, S. Orsola-Malpighi Teaching Hospital, Bologna - Italy
  • Profazio, Vincenzo [PubMed] [Google Scholar]
    Ophthalmology Unit, Alma Mater Studiorum University of Bologna, S. Orsola-Malpighi Teaching Hospital, Bologna - Italy
  • Giannaccare, Giuseppe [PubMed] [Google Scholar]
    Ophthalmology Unit, Alma Mater Studiorum University of Bologna, S. Orsola-Malpighi Teaching Hospital, Bologna - Italy
  • Fresina, Michela [PubMed] [Google Scholar]
    Ophthalmology Unit, Alma Mater Studiorum University of Bologna, S. Orsola-Malpighi Teaching Hospital, Bologna - Italy
  • Campos, Emilio C. [PubMed] [Google Scholar]
    Ophthalmology Unit, Alma Mater Studiorum University of Bologna, S. Orsola-Malpighi Teaching Hospital, Bologna - Italy

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.